Back to Stocks

MCRB

Seres Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Seres Therapeutics has aggressively transitioned from a high-burn clinical entity into a streamlined platform focused on high-value inflammatory and immune indications.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a 'lean reset,' Seres is facing a critical liquidity crunch.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every MCRB filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing depicts a company at a crossroads, balancing promising clinical data against an existential financial crisis. The strategic shift toward a partnership-driven model is a logical response to the exhaustion of internal capital, but it leaves the company with very little margin for error. The transition from a diversified business to a concentrated bet on the SER-155 and SER-603 platforms has increased the volatility of the investment thesis. Ultimately, the impact of this filing is a binary outcome for investors. The ability to secure a non-dilutive partnership will validate the platform's value and provide the necessary runway to execute on the I&I pivot. Conversely, the combination of a going concern warning and a looming Nasdaq bid-price risk suggests that without a rapid capital infusion, the company's ability to realize the value of its intellectual property is under severe threat.

Selected Quarter

Core Takeaway

Seres is attempting to survive by cutting costs and seeking partners, but its cash runway is dangerously short.

Investor Lens

The trade-off is between the high-conviction clinical data of the microbiome platform and the immediate risk of insolvency.

Watch Next

Results from the SER-155 investigator-sponsored trial at Memorial Sloan Kettering and any partnership announcements.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.53Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
neutralMay 5

Appointment of Interim CEO and new COO/President roles effective March 2, 2026.

management change
50%
bearishMay 5

Net loss of $19.9 million for the quarter despite significant cost-cutting measures.

margin compression
70%
bearishMay 5

Going concern warning and reliance on ATM offerings indicate imminent need for capital.

dilution risk
90%
neutralMay 5

Appointment of Interim CEO and new COO/President roles effective March 2, 2026.

management change
50%
bearishMay 5

Net loss of $19.9 million for the quarter despite significant cost-cutting measures.

margin compression
70%
bearishMay 5

Going concern warning and reliance on ATM offerings indicate imminent need for capital.

dilution risk
90%
neutralMay 5

Appointment of Interim CEO and new COO/President roles effective March 2, 2026.

management change
50%
bearishMay 5

Net loss of $19.9 million for the quarter despite significant cost-cutting measures.

margin compression
70%
bearishMay 5

Going concern warning and reliance on ATM offerings indicate imminent need for capital.

dilution risk
90%
neutralMay 5

Appointment of Interim CEO and new COO/President roles effective March 2, 2026.

management change
50%
bearishMay 5

Net loss of $19.9 million for the quarter despite significant cost-cutting measures.

margin compression
70%
bearishMay 5

Going concern warning and reliance on ATM offerings indicate imminent need for capital.

dilution risk
90%
neutralMay 5

Appointment of Interim CEO and new COO/President roles effective March 2, 2026.

management change
50%
bearishMay 5

Net loss of $19.9 million for the quarter despite significant cost-cutting measures.

margin compression
70%
bearishMay 5

Going concern warning and reliance on ATM offerings indicate imminent need for capital.

dilution risk
90%
neutralMay 5

Appointment of Interim CEO and new COO/President roles effective March 2, 2026.

management change
50%
bearishMay 5

Net loss of $19.9 million for the quarter despite significant cost-cutting measures.

margin compression
70%
bearishMay 5

Going concern warning and reliance on ATM offerings indicate imminent need for capital.

dilution risk
90%
neutralMay 5

Appointment of Interim CEO and new COO/President roles effective March 2, 2026.

management change
50%
bearishMay 5

Net loss of $19.9 million for the quarter despite significant cost-cutting measures.

margin compression
70%
bearishMay 5

Going concern warning and reliance on ATM offerings indicate imminent need for capital.

dilution risk
90%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing depicts a company at a crossroads, balancing promising clinical data against an existential financial crisis. The strategic shift toward a partnership-driven model is a logical response to the exhaustion of internal capital, but it leaves the company with very little margin for error. The transition from a diversified business to a concentrated bet on the SER-155 and SER-603 platforms has increased the volatility of the investment thesis. Ultimately, the impact of this filing is a binary outcome for investors. The ability to secure a non-dilutive partnership will validate the platform's value and provide the necessary runway to execute on the I&I pivot. Conversely, the combination of a going concern warning and a looming Nasdaq bid-price risk suggests that without a rapid capital infusion, the company's ability to realize the value of its intellectual property is under severe threat.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.